Articles tagged with Plasmodium Infections
Researchers have uncovered how the human immune system fights Plasmodium vivax, paving the way for an effective vaccine against the most widespread form of malaria. The study identifies specific targets on the parasite and explains how antibodies function to prevent and clear infection.
Public Health Alerts provide concise, data-driven information on disease outbreaks and urgent health events. The new series, launched by NEJM Evidence and CIDRAP, offers expert-reviewed reports to support public health evidence-based care.
Researchers have developed a new antimalarial drug candidate, MK-7602, which targets the malaria parasite at multiple stages of its life cycle. The compound has shown potent activity against both Plasmodium falciparum and Plasmodium vivax, two common malaria parasites affecting humans.
Malaria messaging has been shown to increase the use of insecticide-treated nets, particularly among women in Uganda. The study used propensity score matching to isolate the effect of messaging, finding a 5.1% increase in net use among exposed women and a 4.3% increase among caregivers of children.
A clinical trial in Africa has discovered a single-dose treatment combining sulfadoxine, pyrimethamine, artesunate, and pyronaridine (SPAP) that is as effective as traditional multi-day treatments in curing uncomplicated malaria. The study addresses the growing threat of drug-resistant malaria parasites and improves treatment adherence.
Researchers have created a model that can handle complex mosquito behavior and its impact on human diseases. The study reveals surprising findings, such as it may be better to let a mosquito bite you in terms of overall transmission.
Researchers at Helmholtz Centre for Infection Research have identified a new drug candidate, Substance 31, that prevents the production of new proteins in malaria parasites. This approach has the potential to break through existing resistances and develop new therapeutic strategies against malaria infections.
Stefan Kappe, a leading expert in genetic engineering of parasites, has been appointed as the new Director of the Center for Vaccine Development and Global Health at UM School of Medicine. He will focus on developing genetically engineered live-attenuated pathogens to combat malaria infection.
The R21/Matrix-M malaria vaccine generates nearly identical antibodies to those following a natural infection, providing strong protection against the earliest life stage of malaria parasites. This long-lasting immunity is effective without requiring further adaptation.
Researchers developed a CRISPR-based gene-editing system that changes a single molecule within mosquitoes, halting malaria-parasite transmission. The new system is designed to genetically spread the malaria resistance trait until entire populations of the insects no longer transfer the disease-causing parasites.
Researchers have made a breakthrough in understanding malaria parasite proteins that could lead to targeted therapies. Two key proteins, PfRAP03 and PfRAP08, regulate gene expression in the apicoplast, a unique organelle found in P. falciparum. The loss of either protein led to parasite death, confirming their essential roles.
Researchers discovered a potential vulnerability in P. falciparum by inducing protein aggregation, leading to reduced parasite growth. The study may lead to novel antimalarial strategies targeting the parasite's internal protein folding machinery.
A potent combination of antimalarial compounds blocks parasite transmission in mosquitoes while circumventing insecticide resistance. The new strategy retains activity even after a year and efficiently kills parasites even when applied to the female mosquito up to four days in advance of infection.
Researchers at SwRI designed netting systems to deliver antimalarial drugs called Endochin-like Quinolones (ELQs) that destroy Plasmodium parasites transmitted by mosquitoes. The findings, published in Nature, show that the two ELQs kill parasites developing within the mosquito, potentially eliminating resistance.
A recent study found significant elevated expression of AID enzyme in B cells during Plasmodium falciparum malaria, linking the parasite to the development of Burkitt lymphoma. Elevated AID levels were also observed in Kenyan children with uncomplicated malaria.
Researchers have identified novel mosquito repellents with high success rates from natural sources, including food and flavoring materials. The team's machine learning-based cheminformatics approach also pinpointed pyrethroid analogs up to 100 times more effective than existing industry standards.
A new study from Uganda documents partial resistance to artemisinin in 11 out of 100 African children with severe malaria, suggesting a growing concern for the efficacy of lifesaving malaria treatments. The study also reveals that 10 patients who were thought to have been cured suffered repeat malaria attacks within 28 days.
Researchers have created the first spatial map of malaria infection in the mouse liver using Spatial Transcriptomics and single-cell RNA-sequencing. This discovery sheds light on the parasite's lifecycle, revealing changes in host cell gene expression near infected areas.
Scientists at the University of California, Riverside, have identified 898 RNA-dependent proteins in the deadliest human malaria parasite, Plasmodium falciparum. These findings could lead to novel therapeutic targets against malaria and highlight the importance of RNAs in biological pathways in the parasite.
A team of scientists developed a technique to rapidly detect genetic changes in malaria parasites using portable MinION sequencers. They demonstrated the first end-to-end, real-time pathogen monitoring from clinical blood samples in rural, resource-limited malaria hotspots.
Scientists have identified specific long noncoding RNAs that regulate gene expression and life cycle progression of the deadly Plasmodium falciparum malaria parasite. The discovery could lead to new therapeutic strategies against malaria.
Research by the Peter Doherty Institute found that inflammation alters plasma composition, hindering parasite maturation. This work reveals a new mechanism slowing down malaria parasite development in the bloodstream.
A breakthrough mRNA vaccine has been developed to target and stimulate protective immune cell responses against malaria. The vaccine combines an RNA-based approach with a liver-specific adjuvant, generating resident memory cells that halt malaria infection in the liver, providing a broader and more protective immune response.
Researchers have made a breakthrough in producing infectious Plasmodium falciparum sporozoites without the need for mosquitoes, paving the way for more effective malaria vaccines. This achievement accelerates the ability to study the parasite's biology and develop new tools for vaccine development.
Researchers have identified a parasitic protein unique to hypnozoites, which could serve as a potential biomarker of latent malaria vivax infections. The findings lay the groundwork for eliminating the disease by detecting its presence.
Researchers found that sapanisertib can kill the malaria parasite at several stages during its life cycle, including in the liver and red blood cells. The study's findings offer new hope against a disease that kills over half a million people annually.
Two fatal cases of airport malaria were reported in Belgium, highlighting the need for healthcare awareness near airports. The most likely route of transmission was through an imported infectious exotic Anopheles mosquito that was possibly brought via the international airport or military airport.
A novel class of bed net that kills mosquitoes resistant to traditional insecticides by making them unable to move or fly significantly reduces malaria infection in children. The study found a 43% reduction in malaria prevalence and 44% reduction in clinical episodes over two years.
Researchers have discovered a fundamental role of the TBK1 enzyme in deciding B cell fate, crucial for developing effective vaccines for diseases like COVID-19 and malaria. The study reveals that TBK1 is necessary for germinal center formation and high-quality antibody production.
Scientists sequenced Plasmodium falciparum genomes to understand malaria parasite populations and track drug resistance biomarkers. The study identified population-specific SNPs that can be used to determine transmission routes and monitor drug resistance.
Researchers have identified global hotspots where bird malaria is spreading rapidly, with significant impacts on bird populations. The study found that climate and forest conditions play a crucial role in predicting infection risks, highlighting the need for conservation efforts to protect bird species from this deadly disease.
A new study published in the New England Journal of Medicine found that a combination of seasonal vaccination with RTS,S/AS01 E and antimalarial drugs significantly reduces clinical episodes, hospital admissions, and deaths from malaria. The results show a 70% reduction in these outcomes compared to current interventions.
A new study led by ISGlobal has identified a gene called PfAP2-HS that allows the malaria parasite to defend itself from febrile temperatures and other adverse conditions within the host. The study found that this gene activates a protective response against high temperatures, helping the parasite survive in the host's environment.
Scientists at Indiana University have identified a new potential target for treating parasitic diseases in human cells. The discovery suggests that chloroplast-like plastids, which are found in single-celled parasites, may play an important role in the cell and could be targets for drug therapies.